No serious adverse reactions of Tamiflu in China

Introduction: the State Administration of supervision has reported the use of Tamiflu (reporter Guo Ying) a few days ago, there were media reports that the use of Tamiflu by foreign people led to serious adverse reactions Yesterday, the State Food and Drug Administration issued a circular on safety and rational use of Tamiflu, pointing out that no serious adverse reactions have been found in China According to the report, as of November 5 this year, the national ADR case report database has included 52 cases of Tamiflu and 57 cases of adverse reactions, mainly involving the gastrointestinal system, showing nausea, dizziness and other symptoms At present, no serious adverse reactions have been reported According to Xinhua news agency, the Ministry of agriculture received a report from the Hubei provincial headquarters for the prevention and control of highly pathogenic avian influenza yesterday The H5N1 subtype highly pathogenic avian influenza epidemic occurred in Xiaonan District, Xiaogan City, Hubei Province After the measures of blocking, killing, disinfecting and emergency immunization of birds in the threatened area were taken, the epidemic was put out After 21 days of testing, no new infectious source has occurred, which is in line with the provisions of the state on lifting the blockade of the epidemic area The blockade was lifted on December 7 Clinical trials of vaccines in China are divided into four categories Report from our newspaper (reporter Guo Ying) yesterday, Yin Hongzhang, director of the biological products Department of the registration department of the State Food and drug administration, introduced the research progress of human avian influenza vaccine in China He said that the Chinese pandemic influenza vaccine that is about to enter the phase I clinical trial is not a phase I clinical trial in the ordinary sense, but a dosage form test for the unpredictable and accurate target immune virus The pandemic influenza vaccine, which is about to undergo clinical trials, will test immunogenicity at four doses in 100 people.